Metabolic (cytoprotective) therapy of menopausal disturbances
The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of menopausal metabolic syndrome (MS), and relevan...
Main Authors: | S. N. Tolstov, V. B. Mychka |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2011-06-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1835 |
Similar Items
-
Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
by: E. V. Tishina, et al.
Published: (2011-06-01) -
Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
by: V. V. Trusov, et al.
Published: (2007-08-01) -
Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension
by: Yu. V. Zhernakova, et al.
Published: (2011-08-01) -
Metabolic syndrome, not menopause, is a risk factor for hypertension in peri-menopausal women
by: Gyu Chul Oh, et al.
Published: (2018-10-01) -
Comparison of metabolic changes after natural menopause and surgical menopause
by: Maryam Farahmand, et al.
Published: (2013-12-01)